Table 1.
Demographics and clinical characteristics of US veterans treated for MM
| US veterans diagnosed with MM between 9/1/1999 and 6/30/2014 (full cohort, n = 4446) | US veterans diagnosed with MM between 7/1/2006 and 6/30/2014 (post‐lenalidomide cohort, n = 2837) | |||||
|---|---|---|---|---|---|---|
| VTE n = 327 (7.4%) | No VTE n = 4119 (92.6%) | P value | VTE n = 185 (6.5%) | No VTE n = 2652 (97.5%) | P value | |
| Mean age, y | 67.3 | 68.5 | .051 a | 67.6 | 68.5 | .28 a |
| Male, n (%) | 96.9 (317) | 98.0 (4035) | .22 b | 96.2 (178) | 97.8 (2594) | .19 b |
| Mean Charlson‐Romano Comorbidity Index | 2.9 | 3.4 | .005 a | 3.3 | 3.7 | .13 a |
| Race | .65 b | .59 b | ||||
| White/Other | 71.3 (233) | 70.1 (2886) | 71.4 (132) | 69.5 (1842) | ||
| Black | 28.7 (944) | 29.9 (1233) | 28.6 (53) | 30.5 (810) | ||
| BMI (%) | .009 c | .02 c | ||||
| <18.5 | 0.6 (2) | 2.5 (104) | 0.5 (1) | 2.3 (60) | ||
| 18.5‐<25 | 27.8 (91) | 31.1 (1281) | 25.4 (47) | 30.4 (805) | ||
| 25‐<30 | 38.5 (126) | 38.7 (1593) | 38.4 (71) | 37.8 (1003) | ||
| ≥30 | 33.0 (108) | 27.7 (1141) | 35.7 (66) | 30.0 (784) | ||
| VTE before MM (%, n) | 4.9 (16) | 2.3 (93) | .003 b | 5.4 (10) | 2.9 (77) | .06 b |
| Anemia (%) | 39.8 (130) | 40.6 (1671) | .77 b | 37.3 (69) | 40.2 (1065) | .44 b |
| CrCl < 30 mL/min (%) | 20.2 (66) | 22.7(933) | .33 b | 18.9 (35) | 22.1(586) | .31 b |
| Albumin (mean) | 3.3 | 3.3 | .66 | 3.3 | 3.3 | .81 |
| Transplant in 1 y after diagnosis (%, n) | 14.1 (46) | 8.9 (366) | .002 b | 12.4 (23) | 10.0 (266) | .30 b |
| Melphalan in 1 y after diagnosis (%, n) | 25.1 (82) | 25.7 (1181) | .17 b | 20.0 (37) | 19.2 (508) | .78 b |
| Lenalidomide use in 1 y after diagnosis (%, n) | 22.6(74) | 22.7 (933) | .99 b | 38.4(71) | 34.6 (918) | .30 b |
| Thalidomide use in 1 y after diagnosis (%, n) | 43.7 (143) | 30.1 (1239) | <.001 b | 30.8 (57) | 24.6 (651) | .06 b |
| Bortezomib use in 1 y after diagnosis (%, n) | 31.2 (102) | 33.5 (1379) | .40 b | 47.0 (87) | 48.6 (1289) | .68 b |
| Mean number of therapies in first regimen (mean) | 2.1 | 2.0 | .01 a | 2.2 | 2.0 | .04 a |
| Treatment with ≥3 therapies in first regimen (%, n) | 22.3 (73) | 18.1 (746) | .06 b | 25.9 (48) | 21.5 (571) | .16 b |
Abbreviations: BMI, body mass index; CrCl, creatinine clearance; MM, multiple myeloma; VTE, venous thromboembolism.
a
t test.
b
Chi‐square.
c
Cochran‐Mantel‐Haenszel (row mean score) test.